GlassScriptPhysician profile
Michelle Gauntlett
NPI 1487908950
$4,964.46
in general payments reported to CMS, 2019-2025
22 companies · $774 in 2025
The $774 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,299 · 2022: $604 · 2023: $598 · 2024: $690 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,061.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,291.21 | 2021-2025 | |
| Amgen INC. | $955.66 | 2021-2025 | Evenity, Tavneos, Enbrel |
| Janssen Biotech, INC. | $686.00 | 2021-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $571.47 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $383.82 | 2021-2022 | |
| Pfizer INC. | $288.80 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $123.38 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.16 | 2021-2025 | Ofev |
| Mallinckrodt Hospital Products INC. | $99.72 | 2021-2022 | |
| Glaxosmithkline, LLC. | $59.04 | 2021-2023 | Benlysta |
| Ani Pharmaceuticals, INC. | $58.61 | 2023-2024 | Purified Cortrophin Gel |
| Radius Health, INC. | $55.93 | 2021-2023 | Tymlos |
| Lilly USA, LLC | $54.03 | 2021-2024 | Taltz |
| Organon LLC | $50.28 | 2022-2025 | Hadlima |
| E.R. Squibb & Sons, L.L.C. | $43.10 | 2021-2025 | Orencia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $30.29 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $26.47 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $22.70 | 2023 | |
| Genentech USA, INC. | $16.34 | 2025 | Actemra |
| Pacira Therapeutics, INC. | $13.69 | 2021 | |
| Amarin Pharma, INC. | $12.93 | 2021 | |
| Biodelivery Sciences International, INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Gauntlett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.